


FORM PTO-1390 (Modified) (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				040283-0196	
				U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/009,567	
INTERNATIONAL APPLICATION NO. PCT/GB00/03008		INTERNATIONAL FILING DATE 08/04/2000		PRIORITY DATE CLAIMED 08/11/1999	
TITLE OF INVENTION Condensed Indoline Derivatives and their use as 5HT ₁ , in particular 5HT _{2C} , Receptor Ligands					
APPLICANT(S) FOR DO/EO/US Jonathan Richard Anthony ROFFEY, James Edward Paul DAVIDSON, Howard Langham MANSELL, Richard John HAMLYN and David Reginald ADAMS					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1.	<input type="checkbox"/>	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.			
2.	<input checked="" type="checkbox"/>	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.			
3.	<input type="checkbox"/>	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).			
4.	<input type="checkbox"/>	A proper Demand for International Preliminary Examination was made by the 19 th month from the earliest claimed priority date.			
5.	<input type="checkbox"/>	A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)			
6.	<input type="checkbox"/>	A translation of the International Application into English (35 U.S.C. 371(c)(2)).			
7.	<input type="checkbox"/>	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> have not been made and will not be made.			
8.	<input type="checkbox"/>	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).			
9.	<input checked="" type="checkbox"/>	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) (5 pgs.).			
10.	<input type="checkbox"/>	A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).			
11.	<input checked="" type="checkbox"/>	Applicant claims small entity status under 37 CFR 1.27 .			
Items 12. to 17. below concern other document(s) or information included:					
12.	<input checked="" type="checkbox"/>	An Information Disclosure Statement under 37 CFR 1.97 and 1.98 with Form PTO/SB/08 and 11 references.			
13.	<input type="checkbox"/>	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
14.	<input type="checkbox"/>	A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.			
15.	<input type="checkbox"/>	A substitute specification.			
16.	<input type="checkbox"/>	A change of power of attorney and/or address letter.			
17.	<input type="checkbox"/>	Other items or information: Notice of Missing Requirements (2 pgs.), letter regarding sequence listing.			

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.50 10/009,567		INTERNATIONAL APPLICATION NO. PCT/GB00/03008		ATTORNEY'S DOCKET NUMBER 040283-0196	
18. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS	
Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO.....\$890.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482).....\$710.00					
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))\$740.00					
Neither international preliminary examination fee (37 CFR 1.482) nor International search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,040.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)\$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$0.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 Months from the earliest claimed priority date (37 CFR 1.492(e))				\$130.00	
Claims	Number Filed		Included in Basic Fee	Extra Claims	Rate
Total Claims		-	20	= 0	\$18.00
Independent Claims		-	3	= 0	\$84.00
Multiple dependent claim(s) (if applicable)					\$280.00
TOTAL OF ABOVE CALCULATIONS =				\$130.00	
Reduction by 1/2 for filing by small entity, if applicable.				\$65.00	
SUBTOTAL =				\$65.00	
Processing fee of \$130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	
TOTAL NATIONAL FEE =				\$65.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				+	
TOTAL FEES ENCLOSED =				\$65.00	
				Amount to be: refunded \$	
				charged \$	
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$65.00 to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. <u>06-1447</u> in the amount of \$0.00 to the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>06-1447</u>. A duplicate copy of this sheet is enclosed.</p>					
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>					
<p>SEND ALL CORRESPONDENCE TO:</p> <p>Foley & Lardner Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5143</p>					
				<p style="text-align: center;">SIGNATURE  40,413</p> <p style="text-align: center;">NAME <u>TODD J. BURNS</u></p> <p style="text-align: center;">for</p> <p style="text-align: center;">REGISTRATION NUMBER 38,011</p>	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jonathan Richard Anthony ROFFEY et al.
Title: Condensed Indoline Derivatives and their use as 5HT, in particular
5HT2C, Receptor Ligands
Appl. No.: 10/009,567
Filing Date: 03/22/2002
Examiner: Unassigned
Art Unit: Unassigned

LETTER REGARDING NOTIFICATION OF MISSING REQUIREMENTS

Commissioner for Patents
Washington, D.C. 20231

Sir:



A Notification of Missing Requirements under 37 U.S.C. § 371 ("Notification") was mailed February 6, 2002. The Notification states, inter alia, that a sequence listing must be provided for the nucleotide and/or amino acid sequence disclosure contained in the application. The undersigned has reviewed the application and has found no nucleotide and/or amino acid sequence disclosed in the application. Accordingly, there is no sequence listing that can be provided.

In the event the PTO disagrees, applicants respectfully request that the PTO point out page number and line number where such nucleotide and/or amino acid sequence disclosure is contained.

Respectfully submitted,

Date: April 5, 2002

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 672-5583
Facsimile: (202) 672-5399

By  M.  4/10/02
for Todd J. Burns
Attorney for Applicant
Registration No. 38,011